These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

491 related items for PubMed ID: 17217373

  • 1. CETP inhibition in cardiovascular risk management: a critical appraisal.
    Dullaart RP, Dallinga-Thie GM, Wolffenbuttel BH, van Tol A.
    Eur J Clin Invest; 2007 Feb; 37(2):90-8. PubMed ID: 17217373
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus.
    de Vries R, Borggreve SE, Dullaart RP.
    Clin Lab; 2003 Feb; 49(11-12):601-13. PubMed ID: 14651331
    [Abstract] [Full Text] [Related]

  • 6. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction.
    Schaefer EJ, Asztalos BF.
    Am J Cardiol; 2007 Dec 03; 100(11 A):n25-31. PubMed ID: 18047849
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [HDL and CETP in atherogenesis].
    Pöss J, Böhm M, Laufs U.
    Dtsch Med Wochenschr; 2010 Feb 03; 135(5):188-92. PubMed ID: 20082258
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction?
    Schaefer EJ, Asztalos BF.
    Curr Opin Cardiol; 2007 Jul 03; 22(4):373-8. PubMed ID: 17556892
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver.
    Gauthier A, Lau P, Zha X, Milne R, McPherson R.
    Arterioscler Thromb Vasc Biol; 2005 Oct 03; 25(10):2177-84. PubMed ID: 16123327
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits.
    Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H.
    Nature; 2000 Jul 13; 406(6792):203-7. PubMed ID: 10910363
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.
    Vergeer M, Bots ML, van Leuven SI, Basart DC, Sijbrands EJ, Evans GW, Grobbee DE, Visseren FL, Stalenhoef AF, Stroes ES, Kastelein JJ.
    Circulation; 2008 Dec 09; 118(24):2515-22. PubMed ID: 19029469
    [Abstract] [Full Text] [Related]

  • 20. A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development.
    Zhao L, Jin W, Rader D, Packard C, Feuerstein G.
    Biochem Pharmacol; 2009 Aug 15; 78(4):315-25. PubMed ID: 19539799
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.